Abstract
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by recurrent nodules and abscesses leading to subsequent scarring and tunnel formation. Despite being a fairly common disease with a significant impact on quality of life, only one drug, adalimumab, is currently US Food and Drug Administration (FDA)-approved for treating HS. However, there are many clinical trials underway to address this gap in care for patients with HS. All clinical trials related to HS as of 10/03/2022 were reviewed via clinicaltrials.gov. Studies on topical or systemic medical therapies were included and available results reported if they were ongoing or completed within 6 months prior to the search. Over 30 drugs with at least 20 different mechanisms of action are currently in development for the treatment of HS. While many of these are in phase 2 trials, several are undergoing phase 3 trials and will likely become viable treatment options in the next 5 years. Following years of limited treatment options for HS, drug development has accelerated significantly, forecasting more treatment possibilities and better disease control for many patients. J Drugs Dermatol. 2023;22(10):1021-1026 doi:10.36849/JDD.7339.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
